Repository logo
 
Publication

Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease

2018Journal article Open access
Simple item page
dc.contributor.authorBernardes, C
dc.contributor.authorRusso, P
dc.contributor.authorCarvalho, D
dc.contributor.authorSaiote, J
dc.contributor.authorRamos, J
dc.date.accessioned2022-01-04T15:53:07Z
dc.date.available2022-01-04T15:53:07Z
dc.date.issued2018
dc.description.abstractIntroduction: Systemic inflammatory diseases are related to an increased risk of lymphoproliferative disorders. Although inflammatory bowel disease (IBD) was also associated with these conditions, population-based studies failed to demonstrate this relationship, and most studies only identified a very small number of cases. In the last few years, concerns arose regarding the role of thiopurines and tumour necrosis factor-alpha (TNF-α)-blocking agents in the development of lymphoma, influencing therapeutic decisions in IBD patients. The aim of this study was to describe a case series of IBD patients who developed a lymphoproliferative disorder in our tertiary referral centre. Material and methods: The clinical records of all IBD patients who were observed in our unit between January 2007 and December 2016 were retrospectively reviewed, and IBD subjects who were diagnosed with a lymphoproliferative disorder were selected. Clinical and demographic data regarding both conditions were collected. Results: Six IBD patients were diagnosed with a lymphoma - 4 Hodgkin lymphomas and 2 B-cell non-Hodgkin lymphomas - of which 3 corresponded to primary colonic lymphomas. Immunohistochemical analysis detected the presence of Epstein-Barr virus in the tumour cells of 2 patients, both of them with Hodgkin lymphomas. Only 2 patients were previously treated with thiopurines or anti-TNF-α drugs; none of the remaining had any history of immunosuppressive treatment. Discussion and conclusions: Despite major attention being currently focused on the effect of treatment, which may play the main role in the increased susceptibility to lymphoma in IBD patients, and although it may be difficult to demonstrate, IBD itself may contribute to the development of lymphoproliferative disorders, particularly primary intestinal lymphomas.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGE Port J Gastroenterol. 2018 Jun;25(4):175-178.pt_PT
dc.identifier.doi10.1159/000484440.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3951
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherKargerpt_PT
dc.subjectHSAC GASpt_PT
dc.subjectAnti-TNF-αpt_PT
dc.subjectInflammatory Bowel Diseasept_PT
dc.subjectLymphomapt_PT
dc.subjectLymphoproliferative Disorderspt_PT
dc.subjectThiopurinespt_PT
dc.titleLymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage178pt_PT
oaire.citation.startPage175pt_PT
oaire.citation.titleGE Portuguese Journal of Gastroenterologypt_PT
oaire.citation.volume25pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
GE Port J Gastro 2018 175.pdf
Size:
162.84 KB
Format:
Adobe Portable Document Format
Download

Collections

GAS - Artigos